FIRST EUROPEAN BRAIN TUMOR PATIENT TREATED WITH GLIASITE SYSTEM.

Proxima Therapeutics, Inc., a developer and marketer of site-specific therapies that deliver internal radiation treatment, has announced that the first patient has been treated outside of the United States with its GliaSite(R) Radiation Therapy System (RTS). The male patient, in his 60s, was treated at Klinikum Saarbrucken for a second recurrence of glioblastoma, and is now recovering at home. Glioblastoma is the most common primary brain tumor and one of the most aggressive forms of brain cancer, primarily effecting adults over the age of 50.

GliaSite RTS, CE Marked and FDA cleared, is a patented device comprised of a balloon catheter that is inserted into the cavity created by the surgical removal of the malignant brain tumor. The device is then filled with Iotrex(R), a proprietary liquid radiation source. Over the course of three to seven days, GliaSite delivers radiation directly to the tissue surrounding the cavity, where tumors are most likely to recur, while reducing radiation exposure to healthy brain tissue.

"GliaSite represents an exciting new option for treating malignant brain tumors in Germany and potentially in other countries. The Klinikum Saarbrucken is dedicated to providing the most advanced treatments for its patients. Offering GliaSite supports our mission of delivering the newest therapies to our patients," said Friedrich Weber, M.D., chairman of the Neurosurgical Clinic at Klinikum Saarbrucken in Germany. "GliaSite enables patients with recurrent malignant brain tumors to now receive additional radiation, which previously had not been an option for many of these patients."

"GliaSite has been used with promising results in the United States and we look forward to seeing it benefit patients internationally through the expertise of physicians like Dr. Weber," said Tim Patrick, chief executive officer of Proxima Therapeutics. "We have recently established distribution partnerships in Germany, Italy and Israel to make this technology more broadly available."

After surgery to remove the tumor, the GliaSite RTS balloon catheter is placed inside the space left by the removal of the malignant brain tumor. Once the patient has recovered from surgery (as soon as three days later), a solution containing Iotrex, a proprietary liquid radiation source specifically designed to treat patients with malignant tumors, is injected into the catheter and fills the balloon. Iotrex delivers radiation to the edges of the tumor cavity, targeting tissue where cancer may remain. The Iotrex remains in the balloon for approximately three to seven days, until the prescribed amount of radiation is delivered. The Iotrex mixture is then withdrawn and the GliaSite RTS catheter is removed.

Physicians and patients who would like more information about GliaSite RTS should visit www.GLIASITE.com. For more information on the Klinikum Saarbrucken, visit www.klinikum- saarbruecken.de.

About Proxima Therapeutics

Based in Alpharetta, Ga., Proxima Therapeutics, Inc. is a privately held medical device company established in 1995 to develop site-specific cancer treatment systems for breast and brain tumors. Products include GliaSite RTS for brain cancer and MammoSite RTS for breast cancer.

For more information, visit http://www.proximatherapeutics.com or call 781/684-0770.